Recurrence rate of hepatocellular carcinoma in patients with hepatocellular carcinoma and compensated liver cirrhosis treated with paritaprevir/ombitasvir/ritonavir, dasabuvir with ribavirin: A Romanian national cohort study

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 20 Dec 2018

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary)
Indications Hepatitis C
Focus Therapeutic Use

Most Recent Events

24 Oct 2018 Results assessing the incidence and predictive factors of SAE cohort of 5853 subjects with liver cirrhosis, presented at the 26th United European Gastroenterology Week
24 Oct 2018 Results (n=22) presented at the 26th United European Gastroenterology Week
07 Dec 2017 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight